/BLU
BLU Stock - BELLUS Health Inc.
Healthcare|BiotechnologyNASDAQ
$14.74+0.03%
+$0.01 (+0.03%) • Jun 28
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.85
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).50
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+0.0%upside
Target: $14.74
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for BLU
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$14.60 – $14.89
TARGET (TP)$14.75
STOP LOSS$13.57
RISK/REWARD1:0.0
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-0.28
52W High$14.76
52W Low$6.38
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Revenue | $16,000 | $16,000 | $15,000 | $26,793 | $25,696 |
| Gross Profit | $-3,514,736,653 | $-2,221,947,831 | $-1,430,417,932 | $-994,486,698 | $25,696 |
| Gross Margin | -21967104.1% | -13887173.9% | -9536119.5% | -3711740.7% | 100.0% |
| Operating Income | $-77,883,000 | $-73,284,000 | $-32,942,000 | $-26,104,863.466 | $-7,272,967.556 |
| Net Income | $-76,080,000 | $-71,224,000 | $-31,796,000 | $-26,408,016.719 | $-6,062,274.693 |
| Net Margin | -475500.0% | -445150.0% | -211973.3% | -98563.1% | -23592.3% |
| EPS | $-0.66 | $-0.90 | $-0.54 | $-0.49 | $-0.18 |
Company Overview
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
0%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🔴 Bearish
0 Bullish0 Neutral/Bearish
Price Targets
No price targets available
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 19th 2023 | RBC Capital Mkts | Downgrade | Sector Perform | - |
Earnings History & Surprises
BLUBeat Rate
44%
Last 16 quarters
Avg Surprise
+0.8%
EPS vs Estimate
Beats / Misses
7/7
2 met exactly
Latest EPS
$-0.08
Q4 2023
EPS Surprise History
Q1 22
+30.8%
$-0.18vs$-0.26
Q2 22
+27.8%
$-0.13vs$-0.18
Q3 22
-12.5%
$-0.18vs$-0.16
Q4 22
-11.1%
$-0.20vs$-0.18
Q1 23
+21.1%
$-0.15vs$-0.19
Q2 23
0.0%
$-0.20vs$-0.20
Q3 23
+25.0%
$-0.18vs$-0.24
Q4 23
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 10, 2024 | — | — | — | — |
Q4 2023 | Nov 13, 2023 | — | $-0.08 | — | — |
Q3 2023 | Aug 9, 2023 | $-0.24 | $-0.18 | +25.0% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-0.20 | $-0.20 | 0.0% | = MET |
Q1 2023 | Mar 21, 2023 | $-0.19 | $-0.15 | +21.1% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-0.18 | $-0.20 | -11.1% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.16 | $-0.18 | -12.5% | ✗ MISS |
Q2 2022 | May 11, 2022 | $-0.18 | $-0.13 | +27.8% | ✓ BEAT |
Q1 2022 | Feb 23, 2022 | $-0.26 | $-0.18 | +30.8% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.22 | $-0.29 | -31.8% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.21 | $-0.23 | -9.5% | ✗ MISS |
Q2 2021 | May 10, 2021 | $-0.14 | $-0.20 | -42.9% | ✗ MISS |
Q1 2021 | Feb 25, 2021 | $-0.13 | $-0.10 | +23.1% | ✓ BEAT |
Q4 2020 | Nov 12, 2020 | $-0.16 | $-0.09 | +43.8% | ✓ BEAT |
Q3 2020 | Aug 13, 2020 | $-0.19 | $-0.14 | +26.3% | ✓ BEAT |
Q2 2020 | May 14, 2020 | $-0.18 | $-0.18 | 0.0% | = MET |
Q1 2020 | Feb 27, 2020 | $-0.12 | $-0.18 | -50.0% | ✗ MISS |
Q4 2019 | Nov 14, 2019 | $-0.11 | $-0.14 | -27.3% | ✗ MISS |
Q3 2019 | Aug 8, 2019 | — | $-0.14 | — | — |
Q2 2019 | May 8, 2019 | — | $-0.08 | — | — |
Latest News
Loading news...
Frequently Asked Questions about BLU
What is BLU's current stock price?
BELLUS Health Inc. (BLU) is currently trading at $14.74 per share. The stock has moved +0.03% today.
What is the analyst price target for BLU?
The average analyst price target for BLU is $14.75, based on 1 analyst.
What sector is BELLUS Health Inc. in?
BELLUS Health Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is BLU's market cap?
BELLUS Health Inc. has a market capitalization of $1.87 billion, making it a small-cap company.
Does BLU pay dividends?
No, BELLUS Health Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAMAM
Ambrx Biopharma Inc.
$28.00
Mkt Cap: $1.8B
ASTH
Astrana Health, Inc.
$23.87
Mkt Cap: $1.2B
CALT
Calliditas Therapeutics AB (publ)
$40.00
Mkt Cap: $1.1B
CINC
CinCor Pharma, Inc.
$29.06
Mkt Cap: $1.3B
CTIC
CTI BioPharma Corp.
$9.10
Mkt Cap: $1.2B
DICE
DICE Therapeutics, Inc.
$47.55
Mkt Cap: $2.3B
FUSN
Fusion Pharmaceuticals Inc.
$21.55
Mkt Cap: $1.8B
LBPH
Longboard Pharmaceuticals, Inc.
$59.98
Mkt Cap: $2.3B
MYOV
Myovant Sciences Ltd.
$26.98
Mkt Cap: $2.6B
PRVB
Provention Bio, Inc.
$24.98
Mkt Cap: $2.4B
Explore stocks similar to BLU for comparison